



## **MLA successfully completes first UK animal stem cell treatment procedures**

- **MLA completes first two animal stem cell therapy procedures in UK**
- **Animal stem cells also harvested and cryo-preserved at TUTAVet laboratory in Hampshire – first of its kind in Europe**
- **Significant pipeline of veterinary surgeons keen to trial technology following exhibition at World Small Animal Veterinary Conference**
- **Actively marketing TUTAVet now in UK and Europe**

**Sydney: 30<sup>th</sup> April 2012:** Medical products and distribution company Medical Australia Limited (ASX:MLA) is pleased to announce that the first two TUTAVet animal stem cell therapy procedures have been successfully performed in the UK by veterinary surgeon Dr. Stewart Halperin, BVM&S MRCVS ACIARB.

As announced by MLA on April 3<sup>rd</sup> 2012, the company has secured the rights to this unique stem cell therapy technology through its licensing agreement with Australian-owned MediVet, which has pioneered the development of stem cell technology for small animals and the equine market. This technology is being offered under the TUTAVet brand name, and is used to treat animal diseases including degenerative joint disease, arthritis and tendon and ligament damage.

The company has also established a laboratory in the UK to commercially cryo-preserve animal stem cells for use in future life, which the company believes is the first in Europe. The TUTAVet offering also involves equipping veterinary practices to perform stem cell procedures in house at point of care, using a suite of laboratory hardware and procedure packs supplied by TUTAVet.

Dr. Stewart Halperin commented: “We are delighted to be the first veterinary practice in the UK to use this cutting edge treatment for improving the quality of animal’s lives. I’m really excited about the difference this will make to pets in the UK; it’s an incredible contribution to animal welfare and a huge leap in medical possibility. TUTAVet have been very supportive in helping us develop the capability to offer this cutting edge stem cell technology to our customers”.

Shortly after the procedures were completed, TUTAVet exhibited at the World Small Animal Veterinary Conference in Birmingham, England. Following this, a significant number of veterinary surgeons are keen to trial the technology in their own practices and the company is in the progress of following up with these vets.

MLA Managing Director Mark Donnison said: “The successful completion of the first two animal stem cell treatment procedures in the UK is a significant achievement for MLA, as we look to move into the lucrative veterinary market. The positive response the company received from the World Small Animal Veterinary Conference is indicative of the demand for stem cell technology, particularly in the UK and Ireland where there are over 5,000 veterinary clinics. We believe this technology has significant commercial upside, and through our TUTAVet offering, we intend developing a significant new revenue stream for MLA.”

### **ENDS**

#### **For more information contact:**

Mark Donnison  
CEO, Medical Australia  
Ph: +61 2 9466 5300

*Medical Australia Limited (ASX : MLA) is a medical company engaged in the manufacture, distribution and sale of a broad range of medical devices used by healthcare facilities and critical care services in global markets. The Company is a leader in Intravenous (IV) Medication Delivery Systems, Surgical Irrigation, Suction and Oxygen Therapy, Safety Sharps Collection and Reuse Prevention and specialised Diagnostic and Laboratory Equipment. Our products are used in three broad areas of healthcare, Human Health; Biological Collection, Processing and Laboratory; and Animal Health.*